Meeting
2023 ASCO Annual Meeting
Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).
Authors
Golnaz Morad
University of Texas MD Anderson Cancer Center, Houston, TX
Golnaz Morad , Yitao Yang , Sheila Duncan , Sherise D. Ferguson , Jennifer Ann Wargo , Elizabeth M. Burton , Hussein A. Tawbi , Michael A. Davies , Han Liang , Isabella Claudia Glitza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2015)
DOI
10.1200/JCO.2023.41.16_suppl.2015
Abstract #
2015
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
First Author: Ida John
Poster
2023 ASCO Annual Meeting
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).
First Author: Isabella Claudia Glitza
Poster
2020 ASCO Virtual Scientific Program
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
First Author: Julia Katharina Schwarze
Poster
2013 ASCO Annual Meeting
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
First Author: Bartosz Chmielowski